Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403029 | 0.89 | OPRM1 (0.33) | OPRM1OGFRL1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL3406467 | 0.88 | OPRM1 (0.33) | OPRM1OGFRL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3400611 | 0.88 | OPRM1 (0.39) | OPRM1OGFRL1OPRK1OPRL1DRD2 | |
| SCHEMBL3409679 | 0.86 | OPRL1 (0.39) | OPRM1OPRL1 | |
| SCHEMBL3402372 | 0.86 | HTR6 (0.34) | OPRM1OGFRL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3428388 | 0.82 | OPRM1 (0.33) | OPRM1OGFRL1OPRK1OPRL1 | |
| SCHEMBL3402346 | 0.78 | MET (0.46) | OPRM1CHRM2CHRM1CHRM3OPRK1 | |
| SCHEMBL3405079 | 0.76 | OPRM1 (0.41) | OPRM1OGFRL1OPRK1OPRL1 | |
| SCHEMBL3405127 | 0.76 | OPRM1 (0.33) | OPRM1CHRM2CHRM1CHRM3OPRL1 | |
| SCHEMBL4094827 | 0.75 | HTR6 (0.37) | OPRM1OGFRL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254864-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2014-05-14 | — | — | EP | claimed |
| EP-2254864-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | claimed |
| WO-2009106307-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| EP-2254864-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2254864-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009106307-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215725-A1 | Substituted 4-aminocyclohexane derivatives | OPRL1, OPRD1, OPRK1 | OPRM1 7/4885OGFRL1 695/4885CHRM2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.